Robotic Surgery for Biliary Tract Cancer

被引:13
|
作者
Kone, Lyonell B. [1 ]
Bystrom, Philip V. [1 ]
Maker, Ajay V. [2 ]
机构
[1] Univ Illinois, Metropolitan Grp Hosp, Chicago, IL 60607 USA
[2] Univ Calif San Francisco, Dept Surg, San Francisco, CA 94143 USA
关键词
cholangiocarcinoma; gallbladder cancer; robotic surgery; biliary tract cancer; klatskin tumor; minimally invasive surgery; HILAR CHOLANGIOCARCINOMA; GALLBLADDER CANCER; RADICAL RESECTION; OUTCOMES;
D O I
10.3390/cancers14041046
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Complete surgical resection of biliary tract cancer provides the best chance at long-term survival. These surgeries are complex and can be associated with high morbidity and prolonged recovery. Minimally invasive approaches have been shown to improve some of these outcomes in other cancers. However, there is a paucity of data in biliary cancer, and even less is known about the outcomes of surgery utilizing a robotic platform. The present review reports the pooled outcomes of robotic surgery for 259 patients with biliary tract cancer. These outcomes are often equivalent to or improved compared to contemporary data on open surgery. The published data lack prospective or randomized studies. Thus, to evaluate any of the potential benefits of robotic surgery for biliary tract cancer, higher-quality studies are needed. Biliary tract cancer consists of cholangiocarcinoma (CC) and gallbladder cancer (GBC). When resectable, surgery provides the best chance at long-term survival. Unfortunately, surgery for these tumors is associated with long operative times, high morbidities, and prolonged hospital stays. Minimally invasive surgery has been shown to impact selected outcomes, including length of stay, in other diseases, and robotic surgery may offer additional advantages compared to laparoscopic surgery in treating bile duct cancers. This is a systematic review of robotic surgery for biliary tract cancer. Predetermined selection criteria were used to appraise the literature. The PRISMA guidelines were followed. In total, 20 unique articles with a total of 259 patients with biliary tract cancer undergoing robotic surgery met the inclusion criteria. For CC and GBC, respectively, the weighted average operative time was 401 and 277 min, the estimated blood loss was 348 and 260 mL, the conversion rate to open was 7 and 3.5%, the all-cause morbidity was 52 and 9.7%, the major morbidity was 12 and 4.4%, the perioperative mortality was 1.4 and 0%, the length of stay was 15 and 4.8 days, the positive margin rate was 27 and 9%, and the number of lymph nodes retrieved was 4.2 and 8. Robotic surgery for biliary tract cancer appears non-inferior to open surgery when compared to the published contemporary data. However, the current literature on the topic is of low quality, and future prospective/randomized studies are needed.
引用
收藏
页数:11
相关论文
共 50 条
  • [21] Biliary tract cancer treatment: 5,584 results from the Biliary Tract Cancer Statistics Registry from 1998 to 2004 in Japan
    Miyakawa, Shuichi
    Ishihara, Shin
    Horiguchi, Akihiko
    Takada, Tadahiro
    Miyazaki, Masaru
    Nagakawa, Takukazu
    JOURNAL OF HEPATO-BILIARY-PANCREATIC SURGERY, 2009, 16 (01): : 1 - 7
  • [22] Nonsurgical therapy of biliary tract cancer
    Vazquez, Ignacio
    Bridgewater, John
    CURRENT OPINION IN GASTROENTEROLOGY, 2011, 27 (03) : 258 - 261
  • [23] Indication of Hepatopancreatoduodenectomy for Biliary Tract Cancer
    Seiko Hirono
    Masaji Tani
    Manabu Kawai
    Shinomi Ina
    Kazuhisa Uchiyama
    Hiroki Yamaue
    World Journal of Surgery, 2006, 30 : 567 - 573
  • [24] Advances in the systemic treatment of therapeutic approaches in biliary tract cancer
    Mirallas, O.
    Lopez-Valbuena, D.
    Garcia-Illescas, D.
    Fabregat-Franco, C.
    Verdaguer, H.
    Tabernero, J.
    Macarulla, T.
    ESMO OPEN, 2022, 7 (03)
  • [25] Gallbladder Cancer: a Subtype of Biliary Tract Cancer Which is a Current Challenge in China
    Qu, Kai
    Liu, Si-Nan
    Chang, Hu-Lin
    Liu, Chang
    Xu, Xin-Sen
    Wang, Rui-Tao
    Zhou, Lei
    Tian, Feng
    Wei, Ji-Chao
    Tai, Ming-Hui
    Meng, Fan-Di
    ASIAN PACIFIC JOURNAL OF CANCER PREVENTION, 2012, 13 (04) : 1317 - 1320
  • [26] Targeted Therapies in Advanced Biliary Tract Cancer: An Evolving Paradigm
    Chakrabarti, Sakti
    Kamgar, Mandana
    Mahipal, Amit
    CANCERS, 2020, 12 (08) : 1 - 21
  • [27] Lymphadenectomy and margin-negative resection for biliary tract cancer surgery in the United States-Differential technical performance by approach
    Kim, Bradford J.
    Newhook, Timothy E.
    Tzeng, Ching-Wei D.
    Ikoma, Naruhiko
    Chiang, Yi-Ju
    Chun, Yun Shin
    Vauthey, Jean-Nicolas
    Cao, Hop S. Tran
    JOURNAL OF SURGICAL ONCOLOGY, 2022, 126 (04) : 658 - 666
  • [28] Risk estimation for biliary tract cancer: Development and validation of a prognostic score
    Schweitzer, Nora
    Fischer, Mareike
    Kirstein, Martha M.
    Berhane, Sarah
    Kottas, Martina
    Sinn, Marianne
    Gonzalez-Carmona, Maria A.
    Balta, Zeynep
    Weismueller, Tobias J.
    Strassburg, Christian P.
    Reineke-Plaass, Tanja
    Bektas, Hueseyin
    Manns, Michael P.
    Johnson, Philip
    Weinmann, Arndt
    Vogel, Arndt
    LIVER INTERNATIONAL, 2017, 37 (12) : 1852 - 1860
  • [29] Experimental HER2-targeted therapies for biliary tract cancer
    Rizzo, Alessandro
    Ricci, Angela Dalia
    Bonucci, Chiara
    Tober, Nastassja
    Palloni, Andrea
    Frega, Giorgio
    Brandi, Giovanni
    EXPERT OPINION ON INVESTIGATIONAL DRUGS, 2021, 30 (04) : 389 - 399
  • [30] Molecular targeted therapies: Ready for "prime time" in biliary tract cancer
    Lamarca, Angela
    Barriuso, Jorge
    McNamara, Mairead G.
    Valle, Juan W.
    JOURNAL OF HEPATOLOGY, 2020, 73 (01) : 170 - 185